Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan. [PDF]
Dermatol Ther (Heidelb)Igarashi A +6 more
europepmc +1 more source
Journal of Cosmetic Dermatology, Volume 25, Issue 11, November 2026.ABSTRACT Objective To investigate the correlation between the dermoscopic severity of telangiectasia and key pathophysiological features in melasma, and to identify the risk factors associated with vascular pattern severity. Methods In this cross‐sectional study, 137 female melasma patients were classified into four vascular types based on dermoscopic ...
Zhenghui Yang +4 more
wiley +1 more source
Real-World Effectiveness and Safety of Ixekizumab in Moderate-to-Severe Plaque Psoriasis in the Indian Population: A Pilot Study. [PDF]
Indian Dermatol Online JSingh T +5 more
europepmc +1 more source
FDA approves Icotyde<sup>TM</sup> (Icotrokinra): a novel IL-23 receptor antagonist for plaque psoriasis. [PDF]
Ann Med Surg (Lond)Abid MA, Abid MH, Hasan AH, Afzal MD.
europepmc +1 more source
Chronic Plaque Psoriasis as a Predictor of Spinal Osteoproliferation on Magnetic Resonance Imaging (MRI). [PDF]
CureusTamsil K +6 more
europepmc +1 more source
Plaque psoriasis on the tongue: case report
Anais Brasileiros de DermatologiaLucas Campos Garcia +3 more
openaire +4 more sources
Trajectory-based profiling of 52-week secukinumab response reveals baseline clinical and transcriptomic differences in plaque psoriasis. [PDF]
Front ImmunolWang X +5 more
europepmc +1 more source
Oral icotrokinra for plaque psoriasis in adults and adolescents. [PDF]
Ann Med Surg (Lond)Habib E, Nahla UA, Haris M, Saddique MN.
europepmc +1 more source
Efficacy and safety of interleukin inhibitors in the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. [PDF]
Front Med (Lausanne)Ming J, Jiang Y, Wu Q, Xiao X, Chen M.
europepmc +1 more source